BioCentury | Nov 8, 2019
Clinical News

AnaptysBio left with slimmer pipeline after eczema candidate fails Phase IIb

AnaptysBio lost over $700 million in market cap Friday after reporting that IL-33 inhibitor etokimab, which it had hoped would compete with blockbuster inflammatory disease drug Dupixent, missed the primary endpoint in a trial to...
BioCentury | Mar 8, 2019
Clinical News

Boehringer reports first data for IL-36R inhibitor in rare type of psoriasis

Boehringer said BI 655130 cleared symptoms of generalized pustular psoriasis within one week in a Phase I trial in seven patients experiencing an acute moderate-to-severe flare of the disease. BI 655130 is a mAb against...
BioCentury | Jan 23, 2018
Distillery Therapeutics


INDICATION: Dermatitis Mouse studies identified nine S. aureus and host factors as targets for treatment of dermatitis associated with S. aureus infections. In primary mouse and human keratinocytes treated with supernatants from S. aureus cultures,...
BioCentury | Oct 10, 2017
Clinical News

AnaptysBio shares double on atopic dermatitis data

AnaptysBio Inc. (NASDAQ:ANAB) gained $35.41 (101%) to $70.41 on Tuesday after reporting data from a Phase IIa trial of lead program ANB020 , an antibody against IL-33, to treat atopic dermatitis. An AnaptysBio spokesperson told BioCentury...
BioCentury | Apr 11, 2017
Clinical News

ANB019: Ph I started

AnaptysBio began a double-blind, placebo-controlled, Australian Phase I trial to evaluate subcutaneous and IV ANB019 in 72 healthy volunteers and 15 patients with plaque psoriasis. Volunteers will receive single doses of 100 mg subcutaneous ANB019...
BioCentury | Jul 16, 2015
Financial News

AnaptysBio raises $40M in series D

Antibody play AnaptysBio Inc. (San Diego, Calif.) raised $40 million in an oversubscribed series D round. BVF Partners and its affiliates; Cormorant Asset Management; Frazier Healthcare; HBM Healthcare Investments; Longwood Capital Partners; and Novo A/S...
BioCentury | Apr 17, 2015
Clinical News

AnaptysBio plans study of first-in-class IL-36R antagonist

Antibody platform company AnaptysBio Inc. (San Diego, Calif.) began IND-enabling studies of first-in-class IL-36R antagonist ANB019 to treat generalized pustular psoriasis (GPP), a rare but life-threatening inherited form of psoriasis for which there are no...
BioCentury | Apr 16, 2015
Product R&D

Antagonizing psoriasis

Despite the heavy competition in psoriasis, AnaptysBio Inc. believes it can make a mark with a first-in-class antibody for a neglected, inherited form of pustular psoriasis caused by a loss-of-function mutation in the proinflammatory cytokine...
Items per page:
1 - 8 of 8